Advanced Medical Solutions Grp PLC Total Voting Rights (4417Y)
31 Dicembre 2019 - 1:18PM
UK Regulatory
TIDMAMS
RNS Number : 4417Y
Advanced Medical Solutions Grp PLC
31 December 2019
31 December 2019
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Total Voting Rights
In accordance with Disclosure and Transparency Rule 5.6.1, the
issued share capital of Advanced Medical Solutions Group plc as at
31 December 2019 comprises 214,890,995 ordinary shares of 5p each
with voting rights. There are no shares held in treasury.
The above figure (214,890,995) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Nicholas AMS@consilium-comms.com
Brown / Olivia Manser
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Patrick Robb / Gary Clarence
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group acquired Sealantis, an Israeli-based
medical device company with a patent-protected internal sealant
technology platform, and Biomatlante, a French-based developer and
manufacturer of innovative surgical biomaterial technologies.
AMS's products, manufactured in the UK, the Netherlands,
Germany, and the Czech Republic, are sold globally via a network of
multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, the Czech
Republic and Russia. The Group has R&D innovation hubs in the
UK and Germany, as well as the recently acquired R&D facility
in Israel. Established in 1991, the Group has approximately 650
employees. For more information please see www.admedsol.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREAAAFDFKNFFF
(END) Dow Jones Newswires
December 31, 2019 07:18 ET (12:18 GMT)
Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Apr 2023 a Apr 2024